Heartflow Inc. upped the price of shares in its IPO for a second time to $19 on Aug. 7 before opening on the Nasdaq as “HTFL” ...

Minghui Pharmaceutical Ltd. announced it is raising $131 million in a pre-IPO financing round Aug. 7. The funds will be used to advance its cancer and inflammatory disease pipeline, which include a PD ...

Quantumpharm Inc., known as Xtalpi Inc., announced receiving $51 million up front from a potential $5.99 billion deal with ...

Just two days after reporting the appointment of a new CEO, Instylla Inc. said it received a premarket approval from the U.S.

Ischemic stroke triggers a strong neuroinflammatory response, with microglial activation and neutrophil infiltration ...

Although congenital aortic valve disease (AVD) is one of the most prevalent types of congenital heart disease, affecting 1% ...

Med-tech companies brought in $18.11 billion through financings in the first seven months of 2025, marking a modest rebound ...

Proteinqure Inc. has received regulatory clearances from the U.FDA and Health Canada to initiate a phase I trial of lead ...

Biopharma companies raised $34.89 billion through financings in the first seven months of 2025, including $5.66 billion in ...

The Nipah virus (NiV) from the Henipavirus genus is a bat-borne zoonotic pathogen that causes encephalitis and acute ...

The U.S. FDA posted an Aug. 6 early alert regarding the use of the Watchman left atrial appendage device by Boston Scientific Corp., citing instances in which the device’s delivery system is ...

Dana-Farber Cancer Institute Inc. has divulged ubiquitin carboxyl-terminal hydrolase 28 (USP28; KIAA1515) inhibitors reported to be useful for the treatment of cancer and autoimmune disease.